Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
Genmab (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide, R-ICE, in adult patients with relapsed/refractory diffuse large B-cell lymphoma, R/R DLBCL, who are eligible for autologous stem cell transplantation, ASCT. Results demonstrated an overall response rate, ORR, of 87 percent, a complete response rate of 65 percent and a partial response of 23 percent. The majority of patients proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30th European Hematology Association 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome being low grade and no discontinuations due to treatment-emergent adverse events. The most common TEAEs were neutropenia, anemia, and thrombocytopenia. CRS occurred in 52 percent; all were low grade and resolved. One patient had immune effector cell-associated neurotoxicity syndrome, which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients; five had serious infections. There were no Grade 5 TEAEs.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Some Israeli weapons firms' stands shuttered at Paris Air Show
The stands of at least two major Israeli defense firms were blocked off to attendees at the Paris Air Show on Monday, in a move Israel said was ordered by the French government following a dispute over the displays. Boards were placed around the pavilions of firms including Elbit Systems and Israel Aerospace Industries (IAI), which were showcasing examples of military hardware. The booths of Rafael and Uvision were also shuttered, according to Reuters. CNBC has not independently verified this report. "Last night, just one day before the Paris Air Show opened in Le Bourget Airport, exhibition organizers acting on behalf of the French government ordered the removal of offensive weapons systems from Israeli defense industry pavilions — breaking with standard practice at defense exhibitions worldwide," Israel's Defense Ministry said in a statement. The ministry said it had told the air show organizers that it rejected the demand, and that the conference staff responded by erecting black walls overnight, blocking the pavilions for the start of the event Monday. "This outrageous and unprecedented decision reeks of policy-driven and commercial considerations... The French are hiding behind supposedly political considerations to exclude Israeli offensive weapons from an international exhibition - weapons that compete with French industries," it said. CNBC has contacted the Paris Air Show organizers and the French government for comment. Israeli defense firms have been promoting new products set to unveil at the Paris event — one of the biggest in the aviation world — such as Elbit's PAWS-2 (HR) infrared missile warning system. Defense is a major focus in Paris this year amid geopolitical tensions and pledges for higher European security spending, along with relatively subdued demand by commercial airlines to place major new orders given existing backlogs. Other defense firms present at the show include the U.S.'s Lockheed Martin and Raytheon, European missile manufacturer MBDA and the Aviation Industry Corporation of China, while hundreds of military delegations are set to attend. "Last night, after our booth was set up and ready for the show, we were asked to remove some of our systems from the booth," IAI's President and CEO Boaz Levy said in a statement. "We tried to negotiate with them, but it seems these orders came from the highest levels in Paris," Levy said, adding the company had received authorization to participate in the show and complied with organizers' requests. The IAI team was blocked from entering the booth, he noted. Levy said he was "shocked" by the decision and alleged discrimination. The move comes amid escalating conflict between Israel and Iran, with deadly air strikes between the countries continuing for a fourth day on Monday. Israel launched a series of strikes Friday targeting locations it said were related to Iran's nuclear program, killing several senior military officials. France's government and President Emmanuel Macron have meanwhile increased their criticism of Israel over its ongoing military operation in Gaza in recent months, with a joint statement from the United Kingdom, France and Canada in May calling the level of human suffering there "intolerable."
The Hill
4 hours ago
- The Hill
Trump's former surgeon general is now one his most pointed critics
Jerome Adams, President Trump's first-term surgeon general, is becoming one of the most prominent voices speaking out against the public health policies and decisions carried out in the president's second term. Adams, known as a relatively low-profile member of the Trump administration during his tenure, has in recent weeks gone on something of a media campaign against the White House's health care choices. During the pandemic, Adams at times broke from Trump, such as when the president downplayed the death toll of SARS-CoV-2 or suggested injecting bleach to combat infections. But now that he's on the outside looking in, the criticism is becoming more frequent. Adams has made veiled criticisms against Trump's latest surgeon general nominee, and he's spoken out directly against Health Secretary Robert F. Kennedy Jr.'s decision to fire every member of a key vaccine advisory panel. The ex-surgeon general has focused his criticism on the lack of credentials of those being placed in top administration positions and what that might mean for public health. 'While I typically try to focus on policies over personalities, it has become necessary to directly address the role of Robert F. Kennedy Jr. as the head of HHS,' Adams said when reached by The Hill. 'His position means he is directly involved in shaping the policies that affect national and global public health, which is why my most recent Times op-ed and social media posts specifically mention him,' he added. 'However, I remain focused on the broader implications of these policies rather than solely on RFKs motivations and actions as an individual.' The Adams criticism has been on a few different topics. Casey Means Soon after Trump replaced Janette Nesheiwat with Casey Means as his surgeon general nominee, Adams took to social media to highlight how Means lacks the credentials of past surgeon generals. Means co-founded Levels, a health technology company that focuses on tracking health information through devices, after leaving a five-year residency program in Oregon. Means then garnered a large following online by expounding on health information aligning with the Make America Healthy Again movement. She is also the sister of Calley Means, who works as an adviser to Kennedy in the Department of Health and Human Services. Opponents of Means's nomination have highlighted her decision to not complete her residency program as well as her medical license having lapsed. Both Trump and Kennedy have backed Means, though Trump has acknowledged he does not know her well. Adams has repeatedly argued for maintaining certain standards for the position. 'The Surgeon General's position as a trusted public health authority and physician makes full training and licensure a critical expectation in addition to an implicit legal requirement,' he wrote on the X after Means was nominated. While initially careful not to mention Means by name, Adams has since made it clear that he does not support her nomination. 'I do not know and have nothing against Dr. Means – but I feel strongly that the person who is leading America's Public Health Service should be held to the same standard as the people he or she is leading,' Adams said online. In an op-ed published by Stat, Adams, a licensed anesthesiologist, noted the past four confirmed U.S. surgeon generals had extensive experience and training relevant to public health policy. Adams before his own confirmation obtained a master's degree in public health and was the health commissioner for Indiana. 'Given the critical nature of this role, it is imperative that the surgeon general possess the requisite qualifications and experience,' he wrote. 'While the president has the prerogative to nominate individuals for public office, the Senate holds the responsibility to confirm these appointments.' Adams isn't the only former surgeon general to oppose Means. One of his predecessors, Richard Carmona who served under former President George W. Bush, said in an op-ed for The Hill that confirming Means to the position would 'undermine the office.' 'We owe it to the American people — and to those who built the Public Health Service on a tradition of merit and mission — to demand the very best,' wrote Carmona. 'Our health, our security and our future depend on it.' In the face of backlash, Kennedy has highlighted Means's atypical background as an asset rather than a disadvantage. 'She walked away from traditional medicine because she was not curing patients,' Kennedy told Fox News anchor Brett Baier. 'She couldn't get anybody within her profession to look at the nutrition contributions to illness, and she said, 'If we're really going to heal people, if we're healers, we can't just be making our life about billing new procedures.'' Derailed vaccine policy When Kennedy announced he was getting rid of the entire sitting Advisory Committee on Immunization Practices (ACIP) for the Centers for Disease Control and Prevention (CDC), Adams was quick to denounce the decision. In an op-ed for Time published the day after the firings, Adams specifically cited Kennedy's pledge that, 'We won't take away anyone's vaccines.' He cited the ACIP firings along with the Food and Drug Administration's (FDA) new framework limiting access to COVID-19 vaccines and the Centers for Disease Control and Prevention (CDC) no longer recommending the shot for children and pregnant women. 'ACIP has been a trusted, science-driven body that ensures vaccines are safe and effective, saving countless lives through its transparent recommendations. Its members, rigorously vetted for expertise and conflicts of interest, provide independent guidance critical to public health. Removing them without clear evidence of misconduct risks replacing qualified scientists with less experienced voices,' he wrote. On social media, he shared concerns he's received that 'HHS officials may have committed perjury during confirmation hearings.' Though he didn't name anyone specific, he did repost epidemiologist and health economist Eric Feigl-Ding who accused Kennedy of telling 'lies, damn lies.' 'We are witnessing what appears to be a coordinated effort to dismantle the United States' vaccine infrastructure,' Adams told The Hill. 'This trend, which began with changes at the FDA, is now extending to the CDC and encompasses issues beyond just COVID-19 vaccines.' 'I have heard concerns from health and medical colleagues, Republican donors, and individuals on Capitol Hill regarding the direction we are headed, and am trying to help give voice to those concerns,' he added. Kennedy on Wednesday announced eight new picks to replace the 17 ACIP members he fired. Among them were some noted spreaders of COVID-19 misinformation. Adams has also expressed ethical concerns about Kennedy's new rule requiring placebo-controlled trials for new vaccines. 'If a vaccine for a serious disease (e.g., measles, polio) already exists and is proven effective, giving participants a placebo instead of the vaccine could expose them to preventable harm or death. This violates ethical principles like 'do no harm' outlined in documents such as the Declaration of Helsinki,' he wrote on X.
Business Insider
7 hours ago
- Business Insider
Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
Genmab (GMAB) announced new results from the Phase 1b/2 EPCORE NHL-2 trial Arm 10, evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and etoposide, R-ICE, in adult patients with relapsed/refractory diffuse large B-cell lymphoma, R/R DLBCL, who are eligible for autologous stem cell transplantation, ASCT. Results demonstrated an overall response rate, ORR, of 87 percent, a complete response rate of 65 percent and a partial response of 23 percent. The majority of patients proceeded to ASCT. At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression free, and 100 percent of patients were alive. These results were shared today during an oral presentation at the 30th European Hematology Association 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome being low grade and no discontinuations due to treatment-emergent adverse events. The most common TEAEs were neutropenia, anemia, and thrombocytopenia. CRS occurred in 52 percent; all were low grade and resolved. One patient had immune effector cell-associated neurotoxicity syndrome, which resolved. No clinical tumor lysis syndrome was observed. Infections occurred in 18 patients; five had serious infections. There were no Grade 5 TEAEs. Confident Investing Starts Here:
